, Sept. 8 -- Russia's experimental cancer vaccine has successfully cleared preclinical trials, proving both safe and highly effective, according to Russian state news agency TASS.

Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA), announced at the Eastern Economic Forum (EEF) that the vaccine has been in development for several years, with the past three devoted to mandatory preclinical studies.

"The vaccine is ready for use; we are now awaiting official authorization," she said.

Skvortsova said tests showed the vaccine to be safe even after repeated doses, while also producing strong results. Tumor shrinkage and slower progression were recorded in 60-80 percent of cases, depending on the cancer type, along ...